Trials / Recruiting
RecruitingNCT07215390
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-3007, pegcetacoplan (APL-2) | Complement C3 inhibitor |
| DRUG | APL-3007, pegcetacoplan (APL-2) | Complement C3 Inhibitor |
| OTHER | Placebo, Syfovre | Complement C3 Inhibitor |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2027-06-01
- Completion
- 2027-11-01
- First posted
- 2025-10-10
- Last updated
- 2026-03-30
Locations
43 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07215390. Inclusion in this directory is not an endorsement.